Nextech Invest's three globally active oncology funds use a unique combination of tailored investment strategy and pre-clinical and clinical cancer science expertise to tackle the challenges of investing equity in oncology
This de-risking strategy is executed by an investment team with pharmaceutical industry experience working closely with a dedicated scientific board of oncology experts.
By financing a pivotal process of cancer drug development, Nextech Invest thus increases the chance that novel, effective, vital drugs will reach the market, while at the same time offering attractive returns to investors.
Nextech III Oncology LPCI, Nextech Invest's second oncology-focused fund, commenced operations in April 2010. This Swiss limited partnership is fully regulated and operates under the supervision of the Swiss Financial Market Supervisory Authority (FINMA).
Nextech IV Oncology and Nextech V Oncology, Nextech Invest’s third and fourth oncology fund, started operations in September 2014 and 2017, respectively. The Partnerships are regulated under the laws of the Grand Duchy of Luxembourg and are being supervised by the Luxembourg Supervisory Authority for the Financial Sector, the Commission de Surveillance du Secteur Financier (CSSF).
For inquiries please contact Alfred Scheidegger.